Merck KGaA: granted Australian patent for gene editing

(CercleFinance.com) - Germany's Merck said that the Australian Patent Office has allowed the company's patent application for the use of a genome-editing technology.


The patent application covers the potentially game-changing gene editing tool CRISPR, and more specifically how two CRISPR enzymes work together to target a common gene.

Merck is licensing its intellectual property for CRISPR-based insertion of DNA, which corrects genetic defects in the somatic cells of gene therapy patients.

Copyright (c) 2018 CercleFinance.com. All rights reserved.